^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDH6-targeted antibody-drug conjugate

    Related drugs:
    12d
    A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    CDH6 (Cadherin 6)
    |
    raludotatug deruxtecan (DS-6000)
    28d
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=460, Recruiting, Merck Sharp & Dohme LLC | N=280 --> 460
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)
    1m
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=860, Recruiting, Daiichi Sankyo | N=344 --> 860
    Enrollment change • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    2ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (2024-519862-33-01)
    P1, N=30, Not yet recruiting, Oncusp Therapeutics Inc. | N=15 --> 30
    Enrollment change
    |
    CUSP06
    2ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (2024-519862-33-01)
    P1, N=30, Not yet recruiting, Oncusp Therapeutics Inc.
    New P1 trial
    |
    CUSP06
    3ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (2024-519862-33-01)
    P1, N=15, Not yet recruiting, Oncusp Therapeutics Inc.
    New P1 trial
    |
    CUSP06
    4ms
    A clinical study of raludotatug deruxtecan in people with gastrointestinal cancers (MK-5909-005) (2024-517416-30-00)
    P2/3, N=54, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    raludotatug deruxtecan (DS-6000)
    4ms
    REJOICE-GI01: A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    raludotatug deruxtecan (DS-6000)
    5ms
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=860, Recruiting, Daiichi Sankyo | Trial completion date: Dec 2029 --> Apr 2030
    Trial completion date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    8ms
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Merck Sharp & Dohme LLC | N=78 --> 280
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)
    8ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=263, Recruiting, OnCusp Therapeutics, Inc. | N=180 --> 263
    Enrollment change • First-in-human
    |
    CUSP06